<div class="infobox infobox-protein">
| Property | Value |
|----------|-------|
| Protein Name | Lin-7 Homolog B (LIN7B) |
| Gene Symbol | LIN7B |
| Chromosomal Location | 9q34.3 |
| NCBI Gene ID | 5600 |
| UniProt ID | Q9UBR4 |
| Protein Family | LIN2/7/10 (Veli/MALS) family |
| Molecular Weight | ~23 kDa |
| Length | 206 amino acids |
| Subcellular Localization | Postsynaptic density, plasma membrane |
| Brain Expression | High in cortex, hippocampus, cerebellum |
</div>
LIN7B (Lin-7 Homolog B) is a synaptic scaffolding protein belonging to the LIN2/7/10 family, also known as the Veli/MALS (Verprolin Homolog, Discs-Large, LIN-7) family. It plays critical roles in organizing glutamate receptors at postsynaptic densities, maintaining synaptic structure, and regulating synaptic plasticity. This protein is essential for proper synaptic transmission and has been implicated in neurodegenerative diseases including Alzheimer's disease and Parkinson's disease. PMID: 37170986
The LIN7 protein family is evolutionarily conserved from C. elegans to mammals, with three mammalian paralogs: LIN7A (MALS-1), LIN7B (MALS-2), and LIN7C (MALS-3). Each isoform exhibits distinct expression patterns and functional specialization in the brain, though they share common structural features and can form heteromeric complexes [1]. PMID: 31368584
<div class="infobox infobox-protein">
| Property | Value |
|----------|-------|
| Protein Name | Lin-7 Homolog B (LIN7B) |
| Gene Symbol | LIN7B |
| Chromosomal Location | 9q34.3 |
| NCBI Gene ID | 5600 |
| UniProt ID | Q9UBR4 |
| Protein Family | LIN2/7/10 (Veli/MALS) family |
| Molecular Weight | ~23 kDa |
| Length | 206 amino acids |
| Subcellular Localization | Postsynaptic density, plasma membrane |
| Brain Expression | High in cortex, hippocampus, cerebellum |
</div>
LIN7B (Lin-7 Homolog B) is a synaptic scaffolding protein belonging to the LIN2/7/10 family, also known as the Veli/MALS (Verprolin Homolog, Discs-Large, LIN-7) family. It plays critical roles in organizing glutamate receptors at postsynaptic densities, maintaining synaptic structure, and regulating synaptic plasticity. This protein is essential for proper synaptic transmission and has been implicated in neurodegenerative diseases including Alzheimer's disease and Parkinson's disease. PMID: 37170986
The LIN7 protein family is evolutionarily conserved from C. elegans to mammals, with three mammalian paralogs: LIN7A (MALS-1), LIN7B (MALS-2), and LIN7C (MALS-3). Each isoform exhibits distinct expression patterns and functional specialization in the brain, though they share common structural features and can form heteromeric complexes [1]. PMID: 31368584
The human LIN7B gene is located on chromosome 9q34.3 and consists of 5 exons spanning approximately 3.5 kb. The gene encodes a 206-amino acid protein with a molecular weight of approximately 23 kDa. Alternative splicing produces variants with altered C-terminal regions, though the full-length isoform predominates in neuronal tissue. PMID: 24738190
LIN7B contains several conserved domains essential for its scaffolding function:
L27 Domain (N-terminus, aa 1-50): The L27 domain mediates heterodimerization with other LIN7 family members and with LIN2 (MAGUK proteins). This domain forms a tight heterodimeric interface that allows LIN7 proteins to assemble into larger scaffolding complexes. The L27 domain was originally identified in C. elegans lin-7 mutants, which exhibit defective vulval development [2].
PDZ Domain (aa 70-160): The Postsynaptic Density-95/Discs Large/Zonula Occludens-1 (PDZ) domain is the signature feature of LIN7B. This domain binds to specific motifs at the C-terminus of target proteins, including NMDA receptor subunits (particularly NR2A/B), AMPA receptor subunits (GluA1-4), and other synaptic proteins. The PDZ domain of LIN7B has high affinity for type I PDZ-binding motifs (X-S/T-X-Φ, where Φ is hydrophobic) [3].
C-terminal Region (aa 161-206): The C-terminal region contains additional protein-protein interaction sites and localization signals that target LIN7B to the postsynaptic density. This region interacts with PSD-95 family proteins and other MAGUKs [4].
LIN7B serves as a critical organizer of the postsynaptic density through multiple mechanisms:
NMDA Receptor Clustering: LIN7B directly binds to NMDA receptor subunits, particularly NR2A and NR2B, through PDZ domain-mediated interactions. This binding is essential for proper NMDA receptor localization at postsynaptic sites and contributes to synaptic plasticity. Studies using LIN7B knockdown demonstrate reduced NMDA receptor surface expression and impaired synaptic function [5].
AMPA Receptor Targeting: LIN7B interacts with AMPA receptor subunits, particularly GluA1, through a PDZ-binding motif at the GluA1 C-terminus. This interaction is critical for AMPA receptor trafficking to and retention at the postsynaptic membrane. Loss of LIN7B function results in reduced AMPA receptor-mediated synaptic responses [6].
Kainate Receptor Association: LIN7B also binds to kainate receptor subunits, contributing to the localization of these glutamate receptors at synaptic and extrasynaptic sites.
LIN7B integrates into larger synaptic scaffolding complexes:
LIN7/PSD-95 Complex: LIN7B interacts with PSD-95 (DLG4) and related MAGUK proteins through multiple protein-protein interactions. The LIN7-PSD-95 complex forms a stable scaffold that organizes postsynaptic receptors and signaling proteins [7].
Heterotrimeric Complexes: LIN7 proteins can form heterotrimeric complexes with LIN2 (MAGI-2, MAGI-1) proteins. These complexes create a modular scaffold that connects multiple receptor types to downstream signaling pathways.
Interaction with CASK: LIN7B interacts with CASK (Calcium/calmodulin-dependent serine protein kinase), a presynaptic and postsynaptic scaffold that links synaptic proteins to the actin cytoskeleton [8].
LIN7B plays essential roles in both long-term potentiation (LTP) and long-term depression (LTD):
LTP Maintenance: Studies demonstrate that LIN7B is required for the maintenance of LTP. Following LTP induction, LIN7B levels at synapses increase, and blocking LIN7B function impairs LTP maintenance without affecting induction [9].
LTD Induction: LIN7B mediates LTD through regulation of AMPA receptor endocytosis. The protein is involved in the internalization of AMPA receptors during LTD, a process essential for synaptic weakening [10].
Homeostatic Plasticity: LIN7B participates in homeostatic scaling responses, where synapses adjust their strength in response to chronic activity changes. This adaptive response maintains neuronal network stability.
Beyond its postsynaptic roles, LIN7B participates in synaptic vesicle trafficking:
Synaptic Vesicle Targeting: The L27 domain of LIN7B directs synaptic vesicle proteins to the presynaptic plasma membrane. LIN7B associates with synaptic vesicles and facilitates the delivery of vesicle proteins to release sites [11].
Membrane Protein Delivery: LIN7B ensures proper delivery of membrane proteins to the synapse, including receptors and ion channels.
LIN7B exhibits region-specific expression in the central nervous system:
At the cellular level, LIN7B is predominantly:
LIN7B is implicated in Alzheimer's disease pathogenesis through multiple mechanisms:
Synaptic Loss: In AD brains, LIN7B expression is reduced in the hippocampus and cortex. This reduction correlates with cognitive decline and synaptic marker loss. The decrease may contribute to the synaptic failure that underlies cognitive symptoms [12].
Amyloid-Beta Effects: Aβ oligomers interfere with LIN7B-mediated AMPA receptor trafficking. Aβ exposure reduces LIN7B synaptic localization and impairs receptor delivery, contributing to synaptic dysfunction [13].
Tau Pathology: In tauopathy models, LIN7B distribution is altered, with increased somatodendritic localization. This mislocalization may impair synaptic function [14].
Therapeutic Potential: LIN7B represents a potential therapeutic target for AD. Strategies to enhance LIN7B expression or function could restore synaptic receptor trafficking and improve cognitive function.
LIN7B involvement in PD includes:
Synaptic Protein Homeostasis: PD-related proteins (α-synuclein, LRRK2) affect synaptic scaffolding components. LIN7B levels are altered in PD models and patient tissue [15].
Dopaminergic Synapse Function: In dopaminergic neurons, LIN7B organizes glutamate receptors that modulate excitatory inputs to the substantia nigra. Dysregulation may contribute to basal ganglia circuit dysfunction.
LRRK2 Interaction: The PD-associated kinase LRRK2 may phosphorylate proteins involved in LIN7B-mediated trafficking, though direct interaction remains to be established.
Autism Spectrum Disorder: LIN7B is located in a genomic region linked to autism. Copy number variations affecting LIN7B have been reported in ASD patients, suggesting a potential role in social and cognitive function [16].
Intellectual Disability: Rare LIN7B mutations cause non-syndromic intellectual disability. These mutations affect protein-protein interactions and impair synaptic function [17].
Epilepsy: Altered LIN7B expression has been observed in epileptic tissue, potentially contributing to network hyperexcitability.
LIN7B interacts with multiple synaptic proteins:
| Partner | Interaction Type | Functional Role |
|---------|------------------|-----------------|
| NMDA Receptor (NR2A/B) | PDZ-mediated | Receptor localization |
| AMPA Receptor (GluA1) | PDZ-mediated | Receptor trafficking |
| PSD-95 | Protein complex | Scaffold organization |
| CASK | Protein complex | Membrane targeting |
| GRIP1 | PDZ-mediated | Glutamate receptor binding |
| LIN7A/LIN7C | L27 domain | Complex formation |
| LIN2/MAGI | L27 domain | Scaffold assembly |
LIN7B participates in several critical signaling cascades:
Glutamate Receptor Signaling: LIN7B is integral to NMDA and AMPA receptor-mediated signaling. It couples receptors to downstream effectors including CaMKII, MAPK/ERK, and PI3K/Akt pathways.
Synaptic Plasticity Pathways: The protein is involved in LTP/LTD induction and maintenance through regulation of receptor trafficking and downstream signaling.
Actin Cytoskeleton Regulation: LIN7B interactions with CASK and PSD-95 connect receptors to the actin cytoskeleton, regulating spine morphology and size.
LIN7B represents a promising therapeutic target for neurodegenerative diseases because it:
Small Molecule Enhancers: Compounds that stabilize LIN7B interactions or enhance its synaptic localization. No specific LIN7B modulators are currently in development.
Gene Therapy: Viral vector delivery of LIN7B to increase synaptic expression. AAV-mediated LIN7B overexpression has shown promise in preclinical models.
Protein-Protein Interaction Modulators: Peptides or small molecules that enhance LIN7B-receptor interactions.
Cell-Penetrant Peptides: Cell-permeable peptides derived from LIN7B domains that can penetrate neurons and enhance synaptic scaffolding.
Study of LIN7B employs various techniques: